Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...
CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com. Inducement PR Source: Arcus Biosciences ...
CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com.
A transitional B cell population with a distinct transcriptomic signature was expanded in TN-JDM and characterized by higher CD24 and CD5 proteins and less CD39, an immunoregulatory protein. This data ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...
Not rated Dealerships need five reviews in the past 24 months before we can display a rating. (50 reviews) 192 Great Deals out of 1131 listings starting at $5,404 141 Great Deals out of 826 ...
I obtained my PhD in the Statistics and Computational Biology group of Simon Tavare at The University of Cambridge. As part of my thesis I developed open-source software for the analysis of Illumina ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback